- Clinical Trials
Note: When you click on media articles below, a new page will open indicating that you are leaving the Genprex, Inc. website and entering a third-party website not affiliated with Genprex Inc. or any of its affiliates. No information contained in a linked site has been endorsed or approved by Genprex, Inc. and Genprex, Inc. is not responsible for the content of such third-party websites.
Genprex’s President and CEO, Rodney Varner, sits down with CEO/CFO Magazine to talk about Genprex, how it is reprogramming the course of cancer and diabetes and key catalysts in the next 6-12 months.
As a disease involving mutated genes, cancer has always been a key target for emerging gene therapy technologies.
What will it take to transition gene therapy from a treatment for diseases that only affect a few hundred thousand people worldwide to Type 1 diabetes, which is estimated to affect more than 45 million?
Two Austin-based companies involved in medial research say they expect to raise millions of dollars with stock offerings this week.
What do small cap and micro cap investors look at? We thought you’d want to know what we discovered when we took a look back at Channelchek’s most popular content of 2020.
And the winners are …
Genprex Inc. (Nasdaq: GNPX), a gene therapy company headquartered in the Texas capital, took the regional title of the year’s largest increase in share value.
An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).
Genprex announced that quaratusugene ozeplasmid (Reqorsa) will be studied in two new trials, in which non-small cell lung cancer patients with specific molecular markers will receive its investigational drug combined with osimertinib (AstraZeneca’s Tagrisso) or pembrolizumab (Merck’s Keytruda).
Companies are optimizing nonviral delivery methods for commercial use
Austin startup a ripe M&A target for big pharma, one expert says